sunshine presenting data next week. update

DEN PRAIRIE, Minn., Oct. 22, 2013 (GLOBE NEWSWIRE) -- Sunshine Heart, Inc. (Nasdaq:SSH) announced today that its flagship C-Pulse® Heart Assist System will be featured in a clinical presentation at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. The TCT symposium will take place October 27th through November 1st in San Francisco, CA at the Moscone Center.
On Monday, October 28th, an update will be provided on the ongoing European C-Pulse OPTIONS HF study in an oral presentation as part of the day's session entitled, "Device-Based Approaches for Heart Failure: Recent Developments and New Directions." The oral presentation will be included in Session III: LVAD's for "Less Sick Patients," at 10:39 a.m. (PDT) in Moscone West, Room 3009. The oral presentation will be led by Professor Thomas Krabatsch, of The German Heart Center in Berlin, Germany, a worldwide leading center in the treatment of heart failure patients.
In addition, the Company will host an analyst and investor breakfast on Tuesday, October 29th at 7:30 a.m. (PDT) held at the W Hotel San Francisco. Management will provide a brief corporate update followed by physician presentations listed below:
1) Professor Thomas Krabatsch, The German Heart Center, Berlin - Initial Clinical Observations on the OPTIONS HF Trial
2) Dr. Andrew Kao, St. Luke's Mid America Heart Institute, Kansas City - Single Center Experience with C-Pulse Patient Weaning
3) Dr. William Cohn, Texas Heart Institute - Progress with Fully Implantable Pump, Next Steps
The program will conclude with a question and answer session.
About the C-Pulse® Heart Assist System
The C-Pulse Heart Assist System, or C-Pulse System, an investigational device in the United States, Canada and countries that do not recognize the CE mark approval, utilizes the scientific principles of intra-aortic balloon counterpulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. Combined, these potential benefits may help sustain the patient's current condition or, in some cases, reverse the heart failure process, thereby potentially preventing the need for later-stage heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants. It may also provide relief from the symptoms of Class III and ambulatory Class IV heart failure and improve quality of life and cardiac function. Based on the results from our feasibility trial, we also believe that some patients treated with our C-Pulse System will be able to stop using the device due to sustained improvement in their condition as a result of the therapy.

Caution: Investigational device, limited by Federal (or United States) Law to Investigational use.


Read more: http://www.nasdaq.com/press-release/sunshine-heart-to-feature-initial-european-options-hf-data-at-2013-transcatheter-cardiovascular-therapeutics-conference-20131022-00098#ixzz2iRVejlm6